BRAF and metastatic colorectal cancer: The BEACON study confirms that encorafenib plus cetuximab has significant advantages in objective response rate and OS in BRAF V600E-mutated metastatic colorectal cancer (Tabernero et al., 2021) In addition, studies combining encorafenib, cetuximab, and chemotherapy are also underway (Kopetz et al., 2021).